search
Back to results

MOVIN Pilot Randomized Controlled Trial (MOVIN)

Primary Purpose

Depression, Postpartum

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Enhanced Usual Care
MOVIN Care Platform
Sponsored by
Women's College Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Depression, Postpartum

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion criteria:

  1. Residents of Ontario at least 18 years of age
  2. Currently pregnant or mother* of a live infant 0-12 months of age living at the same residence *through natural birth, adoption or surrogacy, including cis women, non-binary and transgender people in all their diversity
  3. EPDS > 12
  4. Registered with a primary care provider

Exclusion criteria:

  1. Experiencing active suicidal ideation (MINI International Neuropsychiatric Interview)
  2. Active substance use disorder (GAIN-SS), current mania or psychosis (MINI Neuropsychiatric Interview)
  3. Unable to access the internet or a device that can support the MOVIN platform
  4. Unable to participate in English
  5. Unable to provide informed consent

Sites / Locations

  • Women's College Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Experimental

Arm Label

Enhanced Usual Care

MOVIN

Arm Description

Access to online resources and educational materials about general mental health, maternal mental health, depression and anxiety in the pregnancy and postpartum period, and an up-to-date listing of treatment services available in Ontario. These resources are maintained by the MOVIN study team.

Enhanced Usual Care plus MOVIN Care Platform. The MOVIN Care Platform is virtual collaborative care intervention with a stepped care approach in which a care coordinator directs participants to one or more evidence-based virtual interventions as appropriate.

Outcomes

Primary Outcome Measures

Feasibility of the trial protocol: Recruitment
Measures of recruitment and retention include rate of recruitment, reason for non-participation and rate of completion of follow-up measures.
Feasibility of the trial protocol: Acceptability
Measures of acceptability include participants' overall experience and satisfaction with and acceptance of the MOVIN platform and the care coordinator, the care coordinator's assessment of the MOVIN platform and its impact on patient care, and primary care providers' assessment of MOVIN's impact on patient care.
Feasibility of the trial protocol: Compliance
Measures of compliance include rate of completion of MOVIN-specific activities, rate of completion of suggested interventions, and rate of resource use.

Secondary Outcome Measures

Feasibility of the trial protocol: Recruitment
Measures of recruitment and retention include rate of recruitment, reason for non-participation and rate of completion of follow-up measures.
Feasibility of the trial protocol: Acceptability
Measures of acceptability include participants' overall experience and satisfaction with and acceptance of the MOVIN platform and the care coordinator, the care coordinator's assessment of the MOVIN platform and its impact on patient care, and primary care providers' assessment of MOVIN's impact on patient care.
Feasibility of the trial protocol: Compliance
Measures of compliance include rate of completion of MOVIN-specific activities, rate of completion of suggested interventions, and rate of resource use.
Maternal clinical outcomes - depression symptoms
Depressive symptoms will be measured using the Edinburgh Postnatal Depressive Scale (EPDS), a self-report scale that has been validated for use in pregnancy and postpartum. EPDS scores range from 0 to 30. EPDS scores >12 are predictive of a diagnosis of depression, with higher scores indicating more severe symptoms.
Maternal clinical outcomes - anxiety symptoms
Anxiety symptoms will be measured using the General Anxiety Disorder-7 (GAD-7) scale, which is a self-report scale with good discriminate validity in perinatal populations. GAD-7 scores range from 0 to 21, with higher scores indicating more severe symptoms.
Maternal clinical outcomes - quality of life
Quality of life will be measured using the 5 Level-5 Dimension EuroQol 5 (EQ-5D-5L) which is a multi-attribute utility instrument for measuring quality-adjusted life year (QALY), a preference-based utility measure of health-related quality of life as perceived by the patient. It can define 3125 different health states ranging from 11111 (full health) to 55555 (worst health).
Health service use: participant time
Measured by participant self-report of activities related to attending appointments and obtaining services.
Health service use: participant cost
Measured by participant self-report of costs related to attending appointments and obtaining services.
Health service use: health system costs
Calculated from participant self-report of medical costs such as hospitalizations, visits with health professionals and medications.
Care coordinator time
Care coordinator time per participant will be measured as the time spent per participant on the MOVIN platform, time spent on phone assessments and other related activities.
Care coordinator cost
Care coordinator cost per participant will be measured as the cost per participant on the MOVIN platform, on phone assessments and other related activities.
Dyadic relationship
The Dyadic Adjustment Scale (DAS) is a self-report measure of relationship adjustment with an intimate partner and will be used to measure relationship distress. The first 15 items of the 32-item measure will be used to assess dyadic consensus. Scores range fro 0 to 75. Higher scores indicate a higher degree of dyadic consensus.
Maternal child relationship
All participants who are postpartum at any time point will complete Parenting Stress Index short form (PSI-SF) to measure parenting stress. This is a 36-item measure consisting of 3 sub-scales: parental distress, dysfunction in the parent-child relations and difficult child. Scores range from 36 to 180. Higher scores indicate higher levels of parenting stress.
Infant temperament
Infant temperament will be measured using the Infant Characteristics Questionnaire (ICQ), an instrument that assesses parental perceptions of difficult infant temperament. Scores range from 28 to 196. Higher scores indicate a higher level of parental perceptions of difficult infant temperament.

Full Information

First Posted
December 7, 2020
Last Updated
April 24, 2023
Sponsor
Women's College Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04680585
Brief Title
MOVIN Pilot Randomized Controlled Trial
Acronym
MOVIN
Official Title
Reproductive Mental Health of Ontario Virtual Intervention Network (MOVIN): A Pilot Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Completed
Study Start Date
April 12, 2021 (Actual)
Primary Completion Date
June 30, 2022 (Actual)
Study Completion Date
December 30, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Women's College Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Despite available treatments for perinatal mood disorders, only 20% of affected women receive treatment that results in remission of symptoms. In order to address gaps in equitable access to treatment the investigators developed the Reproductive Mental health of Ontario Virtual Intervention Network (MOVIN), a virtual collaborative care platform to optimize access for pregnant and postpartum people in Ontario. MOVIN combines collaborative and stepped-care approaches to treatment of perinatal depression and anxiety. The overall objective of this pilot randomized controlled trial (RCT) is to determine the feasibility of implementing a protocol for studying MOVIN for pregnant and postpartum individuals with significant symptoms of depression and anxiety (EPDS > 12) in order to inform the conduct of a larger scale evaluation. O will be randomized to either the MOVIN or control condition and will be asked to complete follow-up assessments 12- and 24-weeks post-randomization. Participants in the MOVIN arm will receive access to the MOVIN platform which includes a care coordinator to help them navigate various virtual treatments. Participants in the control condition will receive a resource list and will navigate the various options on their own.
Detailed Description
People with scores above 12 on the EPDS have a 10 times greater likelihood of having a diagnosis of depression than those with scores with 12 or less, so this is an appropriate cut-off. The primary endpoint is at 12 weeks post-randomization and the secondary endpoint is at 24 weeks post-randomization. Randomization will be performed as block randomization (varying block sizes) with a 1:1 allocation and will be stratified based on EPDS score (13-19 vs. 20 or greater). Participants who score 12 or less on the EPDS in their initial self-referral screen will be informed that they are not at high risk for having depressive or anxiety disorder and the current time, and can re-screen as needed. Participants whose score is in the 9-12 range (i.e. those who are not likely to be experiencing a depressive or anxiety disorder requiring mental health treatment, but might benefit from additional support) will receive an automated message that communicates their score and the acknowledgment of their possible need for support, and provides a list of resources in Ontario that may be helpful for them. These participants will be invited to re-screen at any time into the study, and will be asked permission to be re-contacted in future to determine which supports they used, if any.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression, Postpartum

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
81 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Enhanced Usual Care
Arm Type
Other
Arm Description
Access to online resources and educational materials about general mental health, maternal mental health, depression and anxiety in the pregnancy and postpartum period, and an up-to-date listing of treatment services available in Ontario. These resources are maintained by the MOVIN study team.
Arm Title
MOVIN
Arm Type
Experimental
Arm Description
Enhanced Usual Care plus MOVIN Care Platform. The MOVIN Care Platform is virtual collaborative care intervention with a stepped care approach in which a care coordinator directs participants to one or more evidence-based virtual interventions as appropriate.
Intervention Type
Other
Intervention Name(s)
Enhanced Usual Care
Intervention Description
A standardized handout with information on what treatment options might be useful to start with based on EPDS score and stage of pregnancy or postpartum.
Intervention Type
Other
Intervention Name(s)
MOVIN Care Platform
Intervention Description
Virtual collaborative care intervention with a stepped care approach in which a care coordinator directs participants to one or more evidence-based virtual interventions as appropriate.
Primary Outcome Measure Information:
Title
Feasibility of the trial protocol: Recruitment
Description
Measures of recruitment and retention include rate of recruitment, reason for non-participation and rate of completion of follow-up measures.
Time Frame
12 weeks post randomization
Title
Feasibility of the trial protocol: Acceptability
Description
Measures of acceptability include participants' overall experience and satisfaction with and acceptance of the MOVIN platform and the care coordinator, the care coordinator's assessment of the MOVIN platform and its impact on patient care, and primary care providers' assessment of MOVIN's impact on patient care.
Time Frame
12 weeks post randomization
Title
Feasibility of the trial protocol: Compliance
Description
Measures of compliance include rate of completion of MOVIN-specific activities, rate of completion of suggested interventions, and rate of resource use.
Time Frame
12 weeks post randomization
Secondary Outcome Measure Information:
Title
Feasibility of the trial protocol: Recruitment
Description
Measures of recruitment and retention include rate of recruitment, reason for non-participation and rate of completion of follow-up measures.
Time Frame
24 weeks post randomization
Title
Feasibility of the trial protocol: Acceptability
Description
Measures of acceptability include participants' overall experience and satisfaction with and acceptance of the MOVIN platform and the care coordinator, the care coordinator's assessment of the MOVIN platform and its impact on patient care, and primary care providers' assessment of MOVIN's impact on patient care.
Time Frame
24 weeks post randomization
Title
Feasibility of the trial protocol: Compliance
Description
Measures of compliance include rate of completion of MOVIN-specific activities, rate of completion of suggested interventions, and rate of resource use.
Time Frame
24 weeks post randomization
Title
Maternal clinical outcomes - depression symptoms
Description
Depressive symptoms will be measured using the Edinburgh Postnatal Depressive Scale (EPDS), a self-report scale that has been validated for use in pregnancy and postpartum. EPDS scores range from 0 to 30. EPDS scores >12 are predictive of a diagnosis of depression, with higher scores indicating more severe symptoms.
Time Frame
12 and 24 weeks post randomization
Title
Maternal clinical outcomes - anxiety symptoms
Description
Anxiety symptoms will be measured using the General Anxiety Disorder-7 (GAD-7) scale, which is a self-report scale with good discriminate validity in perinatal populations. GAD-7 scores range from 0 to 21, with higher scores indicating more severe symptoms.
Time Frame
12 and 24 weeks post randomization
Title
Maternal clinical outcomes - quality of life
Description
Quality of life will be measured using the 5 Level-5 Dimension EuroQol 5 (EQ-5D-5L) which is a multi-attribute utility instrument for measuring quality-adjusted life year (QALY), a preference-based utility measure of health-related quality of life as perceived by the patient. It can define 3125 different health states ranging from 11111 (full health) to 55555 (worst health).
Time Frame
12 and 24 weeks post randomization
Title
Health service use: participant time
Description
Measured by participant self-report of activities related to attending appointments and obtaining services.
Time Frame
12 and 24 weeks post randomization
Title
Health service use: participant cost
Description
Measured by participant self-report of costs related to attending appointments and obtaining services.
Time Frame
12 and 24 weeks post randomization
Title
Health service use: health system costs
Description
Calculated from participant self-report of medical costs such as hospitalizations, visits with health professionals and medications.
Time Frame
12 and 24 weeks post randomization
Title
Care coordinator time
Description
Care coordinator time per participant will be measured as the time spent per participant on the MOVIN platform, time spent on phone assessments and other related activities.
Time Frame
12 and 24 weeks post randomization
Title
Care coordinator cost
Description
Care coordinator cost per participant will be measured as the cost per participant on the MOVIN platform, on phone assessments and other related activities.
Time Frame
12 and 24 weeks post randomization
Title
Dyadic relationship
Description
The Dyadic Adjustment Scale (DAS) is a self-report measure of relationship adjustment with an intimate partner and will be used to measure relationship distress. The first 15 items of the 32-item measure will be used to assess dyadic consensus. Scores range fro 0 to 75. Higher scores indicate a higher degree of dyadic consensus.
Time Frame
12 and 24 weeks post randomization
Title
Maternal child relationship
Description
All participants who are postpartum at any time point will complete Parenting Stress Index short form (PSI-SF) to measure parenting stress. This is a 36-item measure consisting of 3 sub-scales: parental distress, dysfunction in the parent-child relations and difficult child. Scores range from 36 to 180. Higher scores indicate higher levels of parenting stress.
Time Frame
12 and 24 weeks post randomization
Title
Infant temperament
Description
Infant temperament will be measured using the Infant Characteristics Questionnaire (ICQ), an instrument that assesses parental perceptions of difficult infant temperament. Scores range from 28 to 196. Higher scores indicate a higher level of parental perceptions of difficult infant temperament.
Time Frame
Baseline, 12 and 24 weeks post randomization
Other Pre-specified Outcome Measures:
Title
Co-variates
Description
We will collect sociodemographic, obstetrical and psychiatric history data. We will also conduct a diagnostic phone interview using the MINI International Neuropsychiatric Interview for major depressive disorder, obsessive-compulsive disorder, panic disorder, agoraphobia, social anxiety disorder, generalized anxiety disorder, alcohol and substance abuse, past (hypo)mania and psychosis, and post-traumatic stress disorder.
Time Frame
Baseline
Title
Maternal birth outcomes
Description
Self-reported pregnancy and birth complications, if applicable.
Time Frame
Baseline, 12 and 24 weeks post randomization
Title
Neonatal birth outcomes
Description
Self-reported neonatal birth outcomes including medical conditions and complications, if applicable.
Time Frame
Baseline, 12 and 24 weeks post randomization

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Residents of Ontario at least 18 years of age Currently pregnant or mother* of a live infant 0-12 months of age living at the same residence *through natural birth, adoption or surrogacy, including cis women, non-binary and transgender people in all their diversity EPDS > 12 Registered with a primary care provider Exclusion criteria: Experiencing active suicidal ideation (MINI International Neuropsychiatric Interview) Active substance use disorder (GAIN-SS), current mania or psychosis (MINI Neuropsychiatric Interview) Unable to access the internet or a device that can support the MOVIN platform Unable to participate in English Unable to provide informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ariel Dalfen, MD
Organizational Affiliation
Women's College Hospital and Sinai Health System
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Simone Vigod, MD, MSc
Organizational Affiliation
Women's College Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Women's College Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5S1B2
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

MOVIN Pilot Randomized Controlled Trial

We'll reach out to this number within 24 hrs